Amedisys, Inc. (NASDAQ:AMED) Receives Consensus Recommendation of “Hold” from Brokerages

Amedisys, Inc. (NASDAQ:AMED) has been given a consensus recommendation of “Hold” by the six research firms that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $100.75.

Separately, Stephens reissued an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a report on Wednesday.

Amedisys Stock Performance

Shares of NASDAQ AMED traded up $0.13 during midday trading on Wednesday, hitting $92.65. The company’s stock had a trading volume of 57,623 shares, compared to its average volume of 269,353. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of 36.76, a P/E/G ratio of 1.82 and a beta of 0.73. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $89.66 and a 200 day moving average price of $93.69. Amedisys has a one year low of $82.15 and a one year high of $98.95.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AMED. National Bank of Canada FI grew its stake in shares of Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock worth $5,365,000 after purchasing an additional 30,213 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Amedisys by 1.3% in the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after acquiring an additional 7,071 shares in the last quarter. Quarry LP purchased a new position in Amedisys during the 3rd quarter valued at $2,569,000. Charles Schwab Investment Management Inc. raised its holdings in Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after purchasing an additional 9,004 shares in the last quarter. Finally, Holocene Advisors LP lifted its position in shares of Amedisys by 391.4% in the 3rd quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider’s stock worth $7,628,000 after purchasing an additional 62,953 shares during the period. 94.36% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.